Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptoragonists (GLP-1 RAs) may offer benefits in obstructive sleep apnea by promotingweight loss and potentially reducing upper airway collapsibility [13].Additionally, type 1 diabetes mellitus (T1DM)—historically managed withoutincretin-based therapies—is gaining attention as a candidate for adjunctiveGLP-1 RA use, with recent studies showing improvements in glycemic variabilityand insulin requirements [14, 15]. The gene discussed is INS; the disease is type 1 diabetes mellitus.